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Abstract
Background: To compare pregnancy complications and birth outcomes for women experiencing nausea and
vomiting in pregnancy, or nausea only, with symptom-free women.
Methods: Pregnancies from the Norwegian Mother and Child Cohort Study (n = 51 675), a population-based
prospective cohort study, were examined. Data on nausea and/or vomiting during gestation and birth outcomes
were collected from three questionnaires answered between gestation weeks 15 and 30, and linked with data from
the Medical Birth Registry of Norway. Chi-squared tests, one way analysis of variance, multiple linear and logistic
regression analyses were used.
Results: Women with nausea and vomiting (NVP) totalled 17 070 (33 %), while 20 371 (39 %) experienced nausea
only (NP), and 14 234 (28 %) were symptom-free (SF). When compared to SF women, NVP and NP women had
significantly increased odds for pelvic girdle pain (adjusted odds ratio, aOR, 2.26, 95 % confidence interval, 95 % CI,
2.09–2.43, and aOR 1.90, 95 % CI, 1.76–2.05, respectively) and proteinuria (aOR 1.50, 95 % CI 1.38–1.63, and 1.20,
95 % CI 1.10–1.31, respectively). Women with NVP also had significantly increased odds for high blood pressure
(aOR 1.40, 95 % CI 1.17–1.67) and preeclampsia (aOR 1.13, 95 % CI 1.01–1.27). Conversely, the NVP and NP groups
had significantly reduced odds for unfavourable birth outcomes such as low birth weight infants (aOR 0.72, 95 % CI
0.60–0.88, and aOR 0.73, 95 % CI 0.60–0.88, respectively) and small for gestational age infants (aOR 0.78, 95 % CI
0.73–0.84, and aOR 0.87, 95 % CI 0.81–0.93, respectively).
Conclusions: We found that women with NVP and NP are more likely to develop pregnancy complications, yet
they display mostly favourable delivery and birth outcomes.
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outcomes, MoBa
* Correspondence: athanasc@medisin.uio.no
1Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical
Sciences, University of Oslo, PO Box 1122, Blindern N-0317 Oslo, Norway
2Department of Nutrition, Institute of Basic Medical Sciences, University of
Oslo, PO Box 1046, Blindern N-0317 Oslo, Norway
Full list of author information is available at the end of the article
© 2015 Chortatos et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chortatos et al. BMC Pregnancy and Childbirth  (2015) 15:138 
DOI 10.1186/s12884-015-0580-6
Background
Nausea and vomiting in pregnancy (NVP) or nausea only
(NP) have been conditions reportedly accompanying ges-
tation for over 4000 years. Global prevalence varies from
approximately 50 to 80 % of all pregnancies [1–5]. The
wide variation may be attributable to a lack of universally
accepted definitions of these two conditions, which span
from slight dizziness and dry retching to continuous
vomiting. Hyperemesis gravidarum (HG) is an extreme
form of NVP, whereby the extent of vomiting may be so
profound that weight loss, electrolyte imbalance, and de-
hydration requiring hospitalisation result [6]. The NVP
condition appears to be so ubiquitous that it has been sug-
gested as being the norm rather than the exception during
pregnancy [7]. The aetiology of NVP remains unknown,
although it is currently believed to be related to early
pregnancy hormones [3, 4].
Lately there has been a resurgence of interest in topics
related to NVP, such as diet, gestational conditions and
birth outcomes [8–10]. In studies addressing pregnancy
complications and birth outcomes for NVP women, re-
sults have often been contradictory. Although previous
studies found no correlation between NVP and compli-
cations such as preeclampsia, diabetes, hypertension, or
proteinuria [1, 5, 11], others reported an increased risk
of gestational diabetes, hypertension, and preeclampsia
for NVP women [8, 12]. Women with NVP were found
more likely to have a longer gestation and a consequent
lower risk of delivering preterm (< week 37) compared
to symptom-free women [5, 13–15], but no association
and an increased risk have also been reported [6, 8, 16,
17]. Birth weight reports have also varied in studies of
differing design and size, with some observing heavier
birth weights from NVP mothers [13, 18, 19], some ob-
serving lighter birth weights [9, 20, 21], and some
reporting no difference [5, 7, 11, 14–17, 22].
Studies exploring birth anomalies have found no sig-
nificant differences in the occurrence of these outcomes
for women with NVP [7, 16, 23, 24], although a few stud-
ies have found a significantly higher number of births with
anomalies or malformations for women with HG [20, 25,
26]. Additionally, NVP has been associated with increased
numbers of female gender births [6, 8, 15, 17, 25, 27], al-
though some studies found no association between NVP
and gender [9, 22, 24], and one study found that NVP was
associated with male gender [28].
The Norwegian Mother and Child Cohort study
(MoBa) includes a large sample of pregnancies, together
with information regarding nausea and vomiting during
pregnancy, providing an ideal opportunity to study some
of the contradictory results in the literature. In addition,
the cohort has been linked with the Medical Birth
Registry of Norway (MBRN), allowing access to key birth
outcomes.
The aim of this paper was to use the MoBa study to
compare pregnancy complications and birth outcomes
in full term pregnancies for the women that experience
NVP or NP, compared with symptom-free (SF) women.
Methods
The Norwegian Mother and Child Cohort Study (MoBa)
MoBa is a prospective population-based pregnancy co-
hort study conducted by the Norwegian Institute of Pub-
lic Health [29]. Participants were recruited from all over
Norway from 1999 to 2008 and the women consented to
participation in 40.6 % of the pregnancies. The women
were asked to answer three questionnaires during preg-
nancy, and follow-up questionnaires were delivered post-
partum at regular intervals. Pregnancy and birth records
from the MBRN were linked to the MoBa cohort [30].
The present study used the quality-assured data files en-
titled ‘version 4’ which consisted of 108 842 children.
Questionnaires and variables
The MoBa data in this study were primarily drawn from
the three self-administered questionnaires answered in
gestational weeks 15 (Q1), 18–22 (Q2), and 30 (Q3),
respectively. Q1 was a general questionnaire covering
details regarding maternal health, lifestyle, demograph-
ics, previous pregnancies, as well as early reports of nau-
sea and/or vomiting. From Q1 we used maternal height
(cm), weight at the start of pregnancy (kg), number of
previous pregnancies, previous experiences of NVP (yes
or no), previous experiences of pelvic girdle pain (PGP;
yes or no), previous preeclampsia (yes or no), diabetic his-
tory pre-pregnancy (yes or no), education (seven categor-
ies collapsed into: ≤12 years, 13–16 years, or ≥17 years),
previous stillbirths or spontaneous miscarriages (yes or
no), and smoking during pregnancy (no, sometimes, or
daily). Maternal body mass index (BMI, kg/m2) was cal-
culated at the start of pregnancy. Parity data from the
MBRN and questions detailing previously occurring
pregnancies from Q1 were combined in order to minim-
ise missing values [31]. Q2 included a semi-quantitative
and validated food frequency questionnaire designed to
capture dietary habits during the first 4–5 months of
pregnancy, enabling assessment of energy intake (kJ)
[32]. Version two of Q2 included detailed questions re-
garding nausea and vomiting, in addition to the food
frequency questionnaire, thus only the women answer-
ing version two were included in this study. The nausea
and vomiting questions probed experiences of nausea or
vomiting during pregnancy (yes or no), the gestational
week of onset and cessation, and whether women were
still experiencing nausea and/or vomiting at the time of
answering the questionnaire.
Data from Q3 enabled us to differentiate NVP cases
from women diagnosed with HG, defined as prolonged
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nausea and vomiting during pregnancy requiring hospi-
talisation before week 25 of gestation. Q3 also provided
data regarding history of high blood pressure prior to
pregnancy (yes or no), PGP (defined as self-reported
mild or severe pain in the anterior and bilateral poster-
ior pelvis, experiences of ≥3 weeks; yes or no), severe
PGP (defined as PGP in addition to the pubic bone
region with severe pain reported in all three pelvic lo-
cations), high blood pressure in pregnancy (≥3 weeks;
yes or no), and proteinuria (≥3 weeks with protein in
urine; yes or no). Women answering Q3 also had an
option to report their highest recorded systolic and dia-
stolic pressure readings. We included one question, an-
swered 6 months postpartum in questionnaire four
(Q4), regarding reasons for caesarean delivery (breech,
previous caesarean delivery, pregnancy complication/ill
mother, poor growth/fetus complication, own prefer-
ence, or other).
Data regarding maternal age (year), parity (para 0, para
1, or para ≥2), gestational length (weeks), preeclampsia
(defined as eclampsia during birth, during pregnancy
and/or post-partum, light or serious preeclampsia, or
HELLP syndrome; eleven categories collapsed into yes
or no), gestational diabetes (five categories collapsed into
yes or no), birth type (five categories collapsed into nor-
mal cephalic or other presentations than normal ceph-
alic), caesarean delivery type (no, planned, emergency, or
unspecified), placental- and birth weights (g), gender of
infant (male or female), body length and head circumfer-
ence of infant (cm), Apgar scores after 5 min (0–10
score categorised into 0–6 or 7–10), birth defects (yes or
no), and infant mortality (eight categories collapsed into
born alive (lived >1 y) or born alive then died ≤1 y post-
delivery) were obtained from the MBRN. Further details
of the diagnostic criteria used in the MBRN for pre-
eclampsia and gestational diabetes can be found else-
where [33, 34]. Birth defects were defined as any birth
defect or malformation registered in the MBRN using
the International Classification of Diseases chapter 17
definition [35, 36]. Gestational length calculations were
based on ultrasound estimates. The small for gestational
age (SGA) variable was created calculating the 10th birth
weight percentile of each gestational week from MoBa
and MBRN data, based on parity (para 0 vs. para ≥1).
Owing to some extreme outlier values for placental- and
birth weights, as well as for body length of infant and
head circumference in the data set of the MBRN, only
values within three standard deviations from the mean
for these variables were included in the analyses: pla-
centa weight 99–1258 g, birth weight 1937–5242 g,
length 43.1–57.6 cm, and head circumference 30.3–
40.3 cm. Outcome questions from either MoBa or the
MBRN allowing only for an answer of ‘yes’ had non-
answers recoded to ‘no’ or ‘none’.
Study sample
The present study included 108 842 children, and exclu-
sions were made for multiple births (n = 3805), and for
women not answering Q1 or only version one of Q2 (n
= 14 190). We also excluded women not answering ver-
sion 2 of Q2 (n = 5390), or questions relating to episodes
of nausea and/or vomiting, or reporting a duration of
nausea or vomiting longer than 26 weeks (n = 3040).
Women recalling NVP symptoms in Q2 contradicting
their previous answers reported weeks earlier in Q1 were
excluded (n = 15 791). Women reporting only vomiting,
or hospitalisation due to HG, and women with an energy
intake outside the range of 4500–20 000 kJ were also ex-
cluded (n = 2358). Women with multiple participation in
MoBa due to additional pregnancies had all but their
first participation excluded (n = 9699). Finally, women
with a gestational length outside weeks 28–42, women
without a full term pregnancy (i.e. non-living births),
and those with missing weight and height at the start of
pregnancy were excluded (n = 2894).
In total, 51 675 women were included in the final
study sample: 17 070 (33 %) reporting NVP, 20 371
(39 %) reporting NP, and 14 234 (28 %) SF. This is the
same sample used in our previous analysis of NVP in
relation to maternal diet and lifestyle, and a detailed de-
scription and flow diagram presenting exclusion criteria
can be found there [10]. Moreover, severity of symptoms
was reported, and the NVP group had a significantly
longer mean duration of nausea than the NP group
(9.6 weeks versus 7.4 weeks, p < 0.001) [10].
Further to these exclusions, women reporting diabetes
pre-pregnancy from Q1 (n = 251) were excluded from
analyses of gestational diabetes, creating a sub-group
called ‘gestational diabetes-no prior history’ (n = 51 424).
Women reporting high blood pressure prior to preg-
nancy from Q3 (n = 1491) were excluded from analyses
of high blood pressure, creating a sub-group called ‘high
blood pressure-no prior history’ (n = 43 089).
Statistical analyses
The study sample was divided into three groups (SF, NP,
or NVP), reflecting answers concerning experiences of
nausea and vomiting. Results are presented as means
(standard deviations; SDs) or frequencies (%). Chi-squared
tests were performed for categorical variables. Outcomes
investigated using logistic regression included PGP, severe
PGP, high blood pressure-no prior history, proteinuria,
preeclampsia, gestational diabetes-no prior history, emer-
gency caesarean delivery, birth type, preterm births
(<37 weeks), Apgar scores after 5 min, low birth weight
(<2500 g), SGA, birth defects, and gender of infant in rela-
tion to group (SF, NP, NVP). Associations between con-
tinuous outcomes (birth weight, body length, and head
circumference) and group (SF, NP, NVP) were studied by
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linear regression. Logistic regression models (except low
birth weight and gender of infant) included maternal age
(continuous), BMI (continuous), smoking during preg-
nancy, parity, education, and gender of infant. Gender of
infant analysis included the same covariates minus gender
of infant. Logistic regression of low birth weight and linear
regression analysis of birth weight, body length, and head
circumference additionally included adjustments for
gestational length (continuous) and energy intake (con-
tinuous). Gestational diabetes, preeclampsia and high
blood pressure-no prior history were also included in
the model analysing birth weight and low birth weight
outcomes, however their addition gave similar results
and were therefore omitted from the presentation of re-
sult. Results are presented as crude odds ratios (cOR)
and adjusted odds ratios (aOR) or mean differences with
95 % confidence intervals (95 % CIs). Statistical inter-
action effects were studied and these results are pre-
sented in supplementary tables. A significance level of
0.05 was used. All analyses were performed using SPSS
20.0 (IBM Corp, Armonk, NY, USA). We have followed
the standard criteria in the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE)
statement (http://www.strobe-statement.org).
Details of ethics approval
The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved
by the Regional Committee for Medical and Health
Research Ethics in South-Eastern Norway Committee A
(REC South East A, reference numbers S-97045 and S-
95113) and the Norwegian Data Protection Authority.
Written informed consent was obtained from all MoBa
participants.
Results
Maternal and gestational history
Maternal demographics and characteristics for the NVP
(33 %), NP (39 %), and SF (28 %) groups relevant for the
multivariable analyses are shown in Table 1. The total
study sample compared with those women excluded
from the sample display similar values in regards mater-
nal age, BMI and energy intake. The proportions of para
0 women, women with ≤12 years education and daily
smokers during pregnancy are slightly lower in the study
sample. However, among the excluded women, 13.2 %
(n = 5438/41 195) had missing values on education and
14.4 % (n = 5922/41 195) had missing values on smoking.
The SF group had the lowest proportion of those with
high blood pressure pre-pregnancy and the highest pro-
portion of those with diabetes pre-pregnancy (Table 2).
Moreover, amongst the para ≥1 women, the SF group
had the lowest proportion of reported previous stillbirths
or spontaneous miscarriages, lowest proportion of previ-
ous experiences of PGP, and the lowest proportion of
previous preeclampsia.
Pregnancy complications
When the NVP and NP groups were compared with the
SF group, we found significantly increased odds for PGP
(aOR 2.26, 95 % CI 2.09–2.43, and aOR 1.90, 95 % CI
1.76–2.05, respectively) and proteinuria (aOR 1.50, 95 %
CI 1.38–1.63, and aOR 1.20, 95 % CI 1.10–1.31, respect-
ively, Table 3). In the analysis of severe PGP, we found a
significant interaction between group and maternal
Table 1 Selected characteristics in relation to group (symptom-free (SF), nausea only (NP), and nausea and vomiting (NVP)),
including total sample used and those excludeda
SF NP NVP Total sample Excludedb
(n = 14 234) (n = 20 371) (n = 17 070) (n = 51 675) (n = 41 195)
Maternal age at delivery (y), n = 51 675 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
30.3 (4.5) 30.8 (4.4) 29.2 (4.6) 30.1 (4.6)
(missing = 0 %)
29.8 (4.8)
(missing = 1 %)
BMI at pregnancy start (kg/m2), n = 51 675 23.9 (4.1) 23.9 (4.1) 24.3 (4.6) 24.0 (4.3)
(missing = 0 %)
24.4 (4.4)
(missing = 16.9 %)
Energy intake (kJ), n = 51 675 9539 (2527.8) 9706.2 (2489.0) 9830.7 (2722.1) 9701.5 (2581.2)
(missing = 0 %)
9644.5 (4170.1)
(missing = 20.8 %)
n (%) n (%) n (%) n (%) n (%)
Parity, n = 51 648 Para 0 8947 (62.9) 9475 (46.5) 9070 (53.2) 27 492 (49.8)
(missing = 0.1 %)
20 513 (53.2)
(missing = 0.7 %)
Maternal education (y), n = 51 675 ≤ 12 y 4200 (30.2) 5535 (27.7) 5755 (34.5) 15 490 (30.0)
(missing = 2.1 %)
13 402 (32.5)
(missing = 13.2 %)
Smoking during pregnancy, n = 51 329 Daily 946 (6.7) 805 (4.0) 803 (4.7) 2554 (4.9)
(missing = 0.7 %)
2629 (6.4)
(missing = 14.4 %)
aExcerpt of sample characteristics from Chortatos et al. [10]
bTotal MoBa sample n = 108 842 children, minus 1906 2nd or 3rd order children from multiple pregnancies = 106 936 women. Minus 51 675 women included in
sample = 55 261. Excluding 14 066 women with ≥1 participation in MoBa gives 41 195 unique cases
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smoking during pregnancy (P = 0.04), whereby the asso-
ciation between group and severe PGP was strongest
among non-smokers (aOR 2.36, 95 % CI 1.90–2.94 for
NP, and aOR 3.50, 95 % CI 2.82–4.34 for NVP, Table 3).
The NVP women also had significantly increased odds
for high blood pressure-no prior history (aOR 1.40, 95 %
CI 1.17–1.67) and preeclampsia (aOR 1.13, 95 % CI
1.01–1.27), when compared to the SF group. Conversely,
the NP group had significantly reduced odds of develop-
ing gestational diabetes-no prior history (aOR 0.76, 95 %
CI 0.58–0.98), compared to the SF group. Of the 888
women with high blood pressure-no prior history, n =
747 recorded a pressure reading. Of these, the mean was
142/88 mmHg in the NVP group (n = 299), 142/
87 mmHg in the NP group (n = 266), and 144/88 mmHg
in the SF group (n = 182). Of those answering ‘yes’ to
high blood pressure prior to pregnancy, n = 550 recorded
a pressure reading (mean 149/97 mmHg).
Delivery and birth outcomes
The SF group had the highest proportions delivering
preterm or with emergency caesarean delivery, in addition
to the highest proportion with a caesarean delivery due to
breech presentation or poor growth/fetus complications
(Table 4). The SF group had infants born with the lowest
mean placental- and birth weights.
The NP group had significantly lower odds of experi-
encing birth outcomes such as an emergency caesarean
delivery (aOR 0.91, 95 % CI 0.84–0.99) or having a
preterm birth (aOR 0.86, 95 % CI 0.78–0.96, Table 5)
when compared to the SF group. Likewise, the NVP
group had significantly lower odds of delivering an in-
fant with a birth type other than normal cephalic. When
analysing Apgar score after 5 min, we found a significant
interaction between group and infant gender (P = 0.001);
both the NVP and NP group had significantly lower
odds of an Apgar score <7 than the SF group if the in-
fant was male. Both NVP and NP groups had signifi-
cantly lower odds of delivering low birth weight infants
or SGA infants than the SF group (aOR 0.72, 95 % CI
0.60–0.88 and aOR 0.73, 95 % CI 0.60–0.88 for low birth
weight, and aOR 0.78, 95 % CI 0.73–0.84 and aOR 0.87,
95 % CI 0.81–0.93 for SGA, respectively, Table 5). No
significant association was found between group and birth
defects (p = 0.15), though an indication of increased odds
ratio was found when comparing the NP group with the
SF group (aOR 1.10, 95 % CI 1.00–1.22). Both NVP and
NP groups had significantly increased odds of having an
infant of female gender compared to SF women.
In linear regression analyses of birth weight we found
that NVP and NP women gave birth to significantly
heavier infants than the SF women (p < 0.001, Table 6).
Likewise, the NP women had significantly longer infants,
with significantly larger head circumferences than the
infants of the SF group (p < 0.001). Several interaction
effects were revealed in the analysis of birth weight and
head circumference (interaction results can be found in
Additional file 1: Table S1).
Table 2 Maternal and gestational history in relation to group (symptom-free (SF), nausea only (NP), and nausea and vomiting (NVP))
SF NP NVP
n (n = 14 234) (n = 20 371) (n = 17 070)
51 675 n (%) n (%) n (%) P valuea
High blood pressure pre-pregnancy 44 580
No 43 089 11 938 (96.9) 17 144 (96.7) 14 007 (96.4)
Yes 1491 380 (3.1) 581 (3.3) 530 (3.6) 0.03
Diabetes pre-pregnancy: 51 675
No 51 424 14 138 (99.3) 20 292 (99.6) 16 994 (99.6)
Yes 251 96 (0.7) 79 (0.4) 76 (0.4) 0.001
Para ≥1 women
Previous stillbirths or spontaneous miscarriages 24 156
No 17 246 3829 (72.5) 7697 (70.7) 5720 (71.6)
Yes 6910 1449 (27.5) 3191 (29.3) 2270 (28.4) 0.045
Previous experience of pelvic girdle pain (PGP) 21 114
No 15 128 3782 (79.4) 6948 (71.4) 4398 (66.5)
Yes 5986 983 (20.6) 2788 (28.6) 2215 (33.5) <0.001
Previous preeclampsia 19 184
No 17 437 4133 (91.9) 8078 (91.7) 5226 (88.9)
Yes 1747 362 (8.1) 735 (8.3) 650 (11.1) <0.001
aChi squared test
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Discussion
In this large cohort we found that women experiencing
NVP and NP collectively reported significantly higher
odds of developing pregnancy complications such as
PGP, severe PGP, high blood pressure, proteinuria, and
preeclampsia, than the SF women did. Conversely, the
NVP and NP women collectively reported significantly
lower odds of unfavourable delivery and birth outcomes,
such as an emergency caesarean delivery, a birth presen-
tation other than normal cephalic, preterm births, low
Apgar scores after 5 min, low birth weight and SGA in-
fants, compared to SF women. The infants of the NVP
and NP women were born heavier, longer, and with a
larger head circumference. In addition, the NVP and NP
women displayed significantly higher odds of giving
birth to female infants.
Owing to our strict delineation between NVP and NP,
caution must be exercised when comparing our results
with previous studies where women with only vomiting,
HG, or with NP and NVP combined have been studied.
Unspecific classifications may contribute to the conflict-
ing results from different studies.
That the NVP women had the highest odds of devel-
oping high blood pressure and proteinuria in pregnancy
supports that they also have the highest odds of develop-
ing preeclampsia, since the pathophysiology and diagno-
sis of preeclampsia includes both maladies [37], and is a
finding supported elsewhere [8]. The mean systolic and
diastolic pressure reported by the three groups promotes
this condition to borderline hypertension by definition
(i.e. ≥140/90 mmHg) [37].
A large retrospective study observing birth outcomes
for women with hypertension in pregnancy found that
these women had increased odds for preterm delivery,
low birth weight infants, and infants with a low Apgar
score [38]. Although this present study focused on dif-
ferent endpoints, the borderline hypertension present in
our NVP and NP groups suggest that NVP may have an
Table 3 Odds ratiosa of pregnancy complications in relation to group (symptom-free (SF), nausea only (NP), and nausea and
vomiting (NVP))
Crude Adjustedd
Outcome Group n (%)b cOR (95 % CI)c P value aOR (95 % CI) P value
Pelvic girdle pain (PGP) SF 1101 (9.2) 1.00 <0.001 1.00 <0.001
NP 2919 (17.3) 2.06 (1.92–2.22) 1.90 (1.76–2.05)
NVP 2845 (20.3) 2.51 (2.33–2.71) 2.26 (2.09–2.43)
Severe pelvic girdle paine <0.001
Smokers SF 30 (3.0) 1.00 1.00
NP 32 (3.9) 1.33 (0.80–2.21) 1.16 (0.69–1.94)
NVP 50 (7.1) 2.50 (1.57–3.98) <0.001 2.20 (1.36–3.56)
Non-smokers SF 105 (1.0) 1.00 1.00
NP 390 (2.9) 2.79 (2.24–3.46) 2.36 (1.90–2.94)
NVP 483 (4.4) 4.32 (3.50–5.33) 3.50 (2.82–4.34)
Proteinuria SF 937 (6.8) 1.00 <0.001 1.00 <0.001
NP 1616 (8.1) 1.22 (1.12–1.32) 1.20 (1.10–1.31)
NVP 1716 (10.4) 1.59 (1.46–1.73) 1.50 (1.38–1.63)
High blood pressure- no prior history SF 209 (1.8) 1.00 <0.001 1.00 <0.001
NP 318 (1.9) 1.06 (0.89–1.27) 1.07 (0.89–1.28)
NVP 361 (2.6) 1.49 (1.25–1.76) 1.40 (1.17–1.67)
Preeclampsia SF 544 (3.9) 1.00 <0.001 1.00 0.004
NP 657 (3.3) 0.83 (0.74–0.94) 0.94 (0.84–1.06)
NVP 735 (4.4) 1.13 (1.01–1.27) 1.13 (1.01–1.27)
Gestational diabetes- no prior history SF 111 (0.8) 1.00 0.08 1.00 0.09
NP 123 (0.6) 0.77 (0.59–0.99) 0.76 (0.58–0.98)
NVP 129 (0.8) 0.97 (0.75–1.25) 0.93 (0.71–1.20)
aOR, odds ratio, logistic regression analysis
bNumber (%) of women with outcome
cCI, confidence interval
dAdjusted for age, body mass index, smoking during pregnancy, parity, education, and gender
eSignificant interaction between severe PGP and smoking status during pregnancy (P = 0.04)
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alternate impact upon these birth outcomes in regards
to the contrasting results for these outcomes found here.
The association between NVP and preeclampsia remains
enigmatic, although severe vomiting has previously been
associated with preeclampsia [12, 39]. Correlations have
been reported for preeclampsia with abnormal levels of
the hormone human chorionic gonadotropin (hCG), as
well as the hormone relaxin in first trimester pregnant
women [37, 40–42]. Both hormones feature prominently
during the first weeks of pregnancy and act in tandem,
appropriately raising suspicion as to their contribution
to NVP [42]. Currently, hCG is primarily suspected of be-
ing responsible for NVP, as the timing of release correlates
with the onset of symptoms [3, 43, 44], although relaxin’s
timing is near identical [42]. It is noteworthy that low
relaxin levels have been implicated in hypertension and
preeclampsia by affecting endothelial vasodilation, and
relaxin as a treatment for preeclampsia is currently under
research [37, 42, 45].
Relaxin has previously been implicated with PGP, how-
ever, its role in PGP is currently inconclusive [46, 47].
Although high levels of relaxin have been suggested as
contributing in the underlying mechanisms of PGP [47],
when examining the other outcomes in our study, low
levels of relaxin seem more plausible for the NVP group
here. In addition to the examples mentioned, relaxin is
also found to be involved in resetting the osmotic
threshold for thirst and antidiuretic hormone release
during early pregnancy [48]. A low level of relaxin would
thus cause a delay in resetting, accompanied by aberrant
water intake patterns, elements that have been suggested
in previous studies [10, 49]. By virtue of the higher
placental- and birth weights observed, the NVP and NP
women have most likely experienced a higher plasma
Table 4 Delivery and birth outcomes in relation to group (symptom-free (SF), nausea only (NP), and nausea and vomiting (NVP))
n SF NP NVP P valuea
51 675 (n = 14 234) (n = 20 371) (n = 17 070)
n (%) n (%) n (%)
Gestation length 51 675 0.001
Normal range 37–42 weeks 49 181 13 460 (94.6) 19 461 (95.5) 16 260 (95.3)
Early birth 35–36 weeks 1545 491 (3.4) 553 (2.7) 501 (2.9)
Very early birth 28–34 weeks 949 283 (2.0) 357 (1.8) 309 (1.8)
Caesarean delivery 51 675 <0.001
No 44 416 12 104 (85.0) 17 654 (86.7) 14 658 (85.9)
Planned caesarean delivery 2544 644 (4.5) 1027 (5.0) 873 (5.1)
Emergency caesarean delivery 4065 1270 (8.9) 1447 (7.1) 1348 (7.9)
Unspecified 650 216 (1.5) 243 (1.2) 191 (1.1)
If yes to caesarean delivery, reason <0.001
Breech presentation 756 283 (29.1) 258 (19.9) 215 (21.0)
Previous caesarean delivery 447 116 (11.9) 194 (14.9) 137 (13.4)
Pregnancy complication/ill mother 650 175 (18.0) 262 (20.2) 213 (20.8)
Poor growth/fetus complication 198 68 (7.0) 83 (6.4) 47 (4.6)
Own preference 314 76 (7.8) 130 (10.0) 108 (10.5)
Other 931 255 (26.2) 371 (28.6) 305 (29.8)
Multiple answers 465
Mortality 51 675 0.60
Born alive, lived >1 y 51 585 14 206 (99.8) 20 340 (99.8) 17 039 (99.8)
Born alive, died ≤1 y 90 28 (0.2) 31 (0.2) 31 (0.2)
Anthropometry Mean (SD) Mean (SD) Mean (SD) P valueb
Weight of placenta at birth (g) 50 115 661.5 (145.2) 677.9 (145.9) 678.3 (144.9) <0.001
Weight of infant at birth (g) 51 106 3561.5 (515.1) 3638.5 (506.4) 3605.5 (508.6) <0.001
Length of infant at birth (cm) 49 180 50.4 (2.1) 50.6 (2.0) 50.4 (2.1) <0.001
Head circ. of infant at birth (cm) 50 319 35.3 (1.5) 35.4 (1.5) 35.3 (1.5) <0.001
aChi squared test
bOne way analysis of variance
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volume expansion than the SF group [50], increasing
their susceptibility to a delayed reset. Furthermore,
abnormal levels of both relaxin and hCG have been im-
plicated with gastrointestinal motility and gastric dys-
rhythmias, which are factors suggested to contribute to
NVP [1, 4, 13, 44, 51], although with an absence of bio-
marker data in this study these associations are specula-
tive. The hCG-relaxin dialogue hints at the complex role
these hormones have in early pregnancy and future NVP
research should consider both hormones when designing
studies. We have been unable to find comparable studies
identifying a relationship between NVP or NP women
and PGP and severe PGP as found here, hence our study
raises new questions regarding this relationship, particu-
larly concerning the possible link in aetiologies for the
two conditions.
The outcomes in this study where NVP and NP vary
in significance suggest that these conditions may have
differing physiological effects upon the body during ges-
tation. Vomiting in itself may affect maternal and fetal
physiology by modulating stress-related and other hor-
monal activity, nutrient intake, and dehydration, much
Table 5 Odds ratiosa of birth outcomes in relation to group (symptom-free (SF), nausea only (NP), and nausea and vomiting (NVP))
Crude Adjustedd
Outcome Group n (%)b cOR (95 % CI)c P value aOR (95 % CI) P value
Emergency SF 1220 (9.4) 1.00 <0.001 1.00 0.07
Caesarean delivery
Preterm birth
NP 1413 (7.6) 0.79 (0.73–0.86) 0.91 (0.84–0.99)
NVP 1302 (8.4) 0.88 (0.81–0.96) 0.97 (0.90–1.06)
SF 751 (5.4) 1.00 <0.001 1.00 0.02
NP 879 (4.4) 0.81 (0.73–0.89) 0.86 (0.78–0.96)
NVP 800 (4.8) 0.88 (0.80–0.98) 0.91 (0.82–1.01)Birth type (other
presentations than
normal cephalic)
SF 1372 (10.3) 1.00 <0.001 1.00 0.001
NP 1780 (9.3) 0.89 (0.82–0.96) 0.97 (0.90–1.04)
NVP 1363 (8.5) 0.81 (0.75–0.87) 0.87 (0.80–0.94)
Apgar score after 5 min (<7)e
Male infants SF 124 (1.6) 1.00 <0.001 1.00 0.006
NP 93 (0.9) 0.56 (0.43–0.73) 0.65 (0.49–0.85)
NVP 90 (1.1) 0.69 (0.53–0.90) 0.75 (0.57–0.99)
Female infants SF 68 (1.1) 1.00 <0.05 1.00 0.03
NP 120 (1.2) 1.13 (0.84–1.52) 1.26 (0.93–1.70)
NVP 74 (0.9) 0.78 (0.56–1.09) 0.85 (0.61–1.19)
Low birth weight SF 339 (2.5) 1.00 <0.001 1.00 0.001
NP 326 (1.7) 0.66 (0.57–0.77) 0.73 (0.60–0.88)f
NVP 305 (1.9) 0.74 (0.64–0.87) 0.72 (0.60–0.88)f
Small for gestational age SF 1657 (12.0) 1.00 <0.001 1.00 <0.001
(SGA) NP 1908 (9.6) 0.78 (0.73–0.84) 0.78 (0.73–0.84)g
NVP 1694 (10.2) 0.84 (0.78–0.90) 0.87 (0.81–0.93)g
Birth defects SF 674 (4.9) 1.00 0.24 1.00 0.15
NP 1022 (5.1) 1.06 (0.96–1.17) 1.10 (1.00–1.22)
NVP 791 (4.8) 0.98 (0.88–1.09) 1.03 (0.93–1.15)
Gender of infant SF 6212 (45.0) 1.00 <0.001 1.00 <0.001
(female) NP 9736 (49.0) 1.18 (1.13–1.23) 1.18 (1.13–1.23)h
NVP 8625 (52.1) 1.33 (1.27–1.39) 1.34 (1.28–1.40)h
aOR, odds ratio, logistic regression analysis
bNumber (%) of women with outcome
cCI, confidence interval
dAdjusted for age, body mass index (BMI), smoking during pregnancy, parity, education, and gender
eSignificant interaction between Apgar score after 5 min (<7) and gender of infant (P = 0.001)
fAdjusted for age, BMI, smoking during pregnancy, parity, education, gender, gestational length, and energy intake
gAdjusted for age, BMI, smoking during pregnancy, education, and gender
hAdjusted for age, BMI, smoking during pregnancy, parity, and education
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as HG does [3, 21, 22, 49]. We found that only the NP
group had significantly lower odds of developing gesta-
tional diabetes. This finding is in contrast to another
study [8], however, this may be due to the unspecific
definitions for NP/NVP already mentioned, as well as
the validity of the diagnosis from the MBRN records
[34]. Although not significant, we observed a trend to-
wards higher odds for birth defects in the NP group, a
finding similar to that of other studies observing NP
women and those only vomiting [24, 52].
All anthropometric measurements of infants were
larger for the NVP or NP group than the SF group,
supporting previous studies [13, 18, 19]. The lower pro-
portion of SGA infants and higher proportion of term
births for the NVP and NP groups undoubtedly contrib-
utes to these outcomes and has been shown elsewhere
[15, 18], yet there may well be other pathways contribut-
ing to this result [3, 53].
We found the NVP and NP women had higher odds
of having a female infant. This finding is supported by
the numerous other studies of HG and NVP [6, 8, 17,
25, 27]. The average Norwegian male-female proportion
of live births between 1999 and 2008 was 51 % male:
49 % female [54], whereas the NVP group in our study
had almost the opposite. It has been suggested that gen-
der of the infant may be affected by such elements as
the timing of intercourse, coital rate, or the hormonal
milieu at the time of conception [55]. Higher levels of
estrogen, estradiol, prolactin and hCG have previously
been reported in NVP and HG pregnancies, suggesting
causal inference regarding gender and NVP [6, 9, 17, 26,
56], although the issue remains speculative.
Strengths and limitations
The strengths of this study are the large population-
based cohort and the linkage to the MBRN, providing
thorough and detailed access to pregnancy and birth
outcomes. While exploring areas related to gestation,
the cohort has specifically addressed NVP-related issues,
thus providing an opportunity to differentiate between
NP and NVP combined. Since we have proceeded to in-
vestigate the same sample featured in our previous study
regarding dietary intakes and NVP [10], this study adds
a comprehensive wealth of information regarding many
outcomes related to the women with NVP and NP. With
such a large cohort size, many significant associations
tend to appear, yet the merit of these in the clinical set-
ting are not always relevant. Weaknesses also include
the reliance on self-reported data from MoBa question-
naires, particularly for nausea and vomiting. Retrospect-
ive evaluation of NVP symptoms has been reported as a
possible source of bias [57]. We attempted to address
this by excluding cases with inconsistencies in NVP
symptoms reported between questionnaires (n = 15 791)
to have as much confidence as possible in the remaining
study sample. When we performed sensitivity analyses
with the excluded cases included in the sample, the re-
sults were mostly unaffected. Women excluded from the
present study tended to have similar ages at delivery,
BMI and energy intake, although there appeared to be
more women with a lower education as well as a higher
parity, findings consistent with non-compliance present
in other studies [58–60]. The higher number of daily
smokers in the excluded group is most likely a product
of the high number of missing values for this variable.
Furthermore, it has been presented elsewhere that al-
though prevalence estimates such as smoking are under-
estimated in the MoBa cohort when compared with the
general Norwegian population, the exposure-outcome
associations are valid [61].
Defining and categorising the difference between
retching and actual vomiting (defining NP and NVP) may
also have affected the results. Endocrine and other diseases
may provide a differential diagnoses for hypertension,
Table 6 Mean difference in birth weight, length, and head circumference for the nausea only (NP) and nausea and vomiting (NVP)
groups compared to the symptom-free (SF) groupa
Crude Adjustedb
Outcome Group Mean (95 % CI) P value Mean (95 % CI) P value
Birth weight (g), n = 51 106 SF reference <0.001 reference <0.001
NP 76.9 (66.0–87.9) 38.4 (29.2–47.6)
NVP 43.9 (32.6–55.4) 20.9 (11.4–30.5)
Body length (cm), n = 49 180 SF reference <0.001 reference <0.001
NP 0.20 (0.16–0.25) 0.11 (0.07–0.15)
NVP 0.08 (0.03–0.12) 0.07 (0.03–0.11)
Head circumference (cm), SF reference <0.001 reference <0.001
n = 50 319 NP 0.12 (0.09–0.15) 0.06 (0.04–0.09)
NVP 0.05 (0.01–0.08) 0.03 (0.00–0.06)
aLinear regression analysis
bAdjusted for age, body mass index, smoking during pregnancy, parity, education, gender, gestational length, and energy intake
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proteinuria, preeclampsia, gestational diabetes and even
nausea and vomiting during pregnancy, however, their oc-
currence in such a large sample would have negligible ef-
fects on the results owing to their low prevalence [4, 62].
Conclusions
We found that women with NVP and NP collectively
had higher odds for pelvic girdle pain, severe pelvic gir-
dle pain, high blood pressure before and during preg-
nancy, proteinuria, and preeclampsia than the SF group.
The NP group had reduced odds of gestational diabetes
with no prior history. The NVP and NP groups collect-
ively had a higher proportion of term births, and lower
odds for an emergency caesarean delivery, birth type
other than normal cephalic, preterm birth, low Apgar
score after 5 min, low birth weight and SGA infants than
the SF group. The NVP and NP groups also had higher
odds of giving birth to a female infant.
To our knowledge, this is the first study finding a rela-
tionship between NVP or NP and PGP or severe PGP.
Importantly, the higher odds for pregnancy complica-
tions during gestation for the NVP and NP women are
counterbalanced by reduced odds for unfavourable deliv-
ery and birth outcomes.
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